Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) announced on Tuesday that it has completed the generation and analysis of all clinical trial and long-term stability data required to support New Drug Application (NDA) submissions for NCX 470 in the United States and China.
The data package, compliant with International Council for Harmonisation guidelines, covers both drug substance and finished drug product and supports manufacturing, shelf-life and drug metabolism requirements.
The company is preparing for a pre-NDA meeting with the US Food and Drug Administration (FDA), with the US NDA submission on track for the first half of 2026 and the China submission expected shortly thereafter. Preparation of the NDA is being funded by licensing partner Kowa.
Nicox confirmed that the Phase 3 clinical program for NCX 470 in Japan was initiated in summer 2025 and is managed and financed by Kowa.
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Neurocrine Biosciences reveals new chapter in R&D strategy
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Physiomics secures follow-on UK contract for Phase 2 study support
Ascletis reports positive US Phase I data for oral IL-17 inhibitor ASC50
Dimerix completes adult recruitment in ACTION3 Phase 3 DMX-200 trial
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL